MarginsXMarginsX
Home › Markets › Health Care › IMA

ImageneBio Inc. (IMA)

IMA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.20
-7.78% on the day
Market cap
$39.9M
Nano cap
Revenue · 2025
$800K
-77.1% on 2024
Net income · 2025
-$45.3M
-5668.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/0001193125-26-099434-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIMA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001835579
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$800K
Net income-$45.3M
Operating income-$48.5M
Net margin-5668.6%
Operating margin-6056.4%
Revenue growth-77.1%
Cash$94.5M
Total assets$153.0M
P/E (computed)Net income was not positive
P/S (computed)49.8×

Warning signs

Cash runway
25.1 months
$84.9M cash at September 30, 2026
Share count, 1 year
+11.4%
2025-11-03 to 2026-10-31 · +209.7% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$79K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$84.9M cash; operating cash flow -$10.2M a quarter.Report 2026-09-30
Shares outstanding12,456,281 (2026-10-31); 11,181,672 a year earlier; 48,258,111 three years earlier. 3y figure adjusted for split (1-for-12 overall).Cover page 2026-10-31
Reverse splits, 3 years1; latest 1-for-12 on 2025-07-28Source 2025-07-28
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-08-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Diego, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-08-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $96K, sold $17K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$15.6M-$9.5M$84.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$10.2M-$9.1M$94.7MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$10.6M-$14.8M$76.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
$0-$6.9M-$7.2M$94.5M$0$800K10-K 2026-03-10
Q3 2025
2025-09-30
$0-$24.8M-$21.5M$103.2M$0$800K10-Q 2026-11-09
Q2 2025
2025-06-30
$0-$7.6M-$11.9M$58.3MNo debt tags$4.3M10-Q 2026-08-05
Q1 2025
2025-03-31
$800K-$6.1M-$7.2M$36.8MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$4.8M-$3.5M$12.1M$8.6M$3.5M10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-08-05
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 339 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.5%
1 month-18.2%
3 months-40.9%
Year to date-49.7%
1 year-58.3%
From 52-week high-57.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TILInstil Bio Inc.$5.75-5.43%$39.0M
CRBUCaribou Biosciences Inc.$0.3528-2.51%$38.1M
EXOZeXoZymes Inc.$3.99+4.18%$37.1M
ELUTElutia Inc.$0.8229+0.35%$36.5M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
INKTMiNK Therapeutics Inc.$9.35+0.11%$48.0M
ELOXEloxx Pharmaceuticals Inc.$12.75-3.04%$51.5M
GRMLGreenland Mines Ltd.$3.50-3.05%$51.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier